Ecuadorian Institute of Social Security

Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
News, Workforce, Gastrointestinal disease, University, Atmosphere, Minneapolis, EMR, Minneapolis Veterans Affairs Health Care System, Endoscopic mucosal resection, Banner Desert Medical Center, EVS, Carbon, Ministry, Hospital, Pentax, MD, Patient, Physician, IBP, Gastroenterology, Ecuadorian Institute of Social Security, R, FDA, MVA, Medical device, Pharmaceutical industry, Cassette tape, Health

The Company incurred non-recurring charges related to these cost-cutting measures of approximately $1.5 million in the first half of 2023.

Key Points: 
  • The Company incurred non-recurring charges related to these cost-cutting measures of approximately $1.5 million in the first half of 2023.
  • Financial Results for the Second Quarter Ended June 30, 2023
    The Company reported revenue of $113,000 for the second quarter 2023, compared to $185,000 for the same period last year.
  • The Company reported $8.5 million in cash and cash equivalents as of June 30, 2023.
  • The Company believes that its cash and cash equivalents as of June 30, 2023 will be sufficient to allow the Company to fund its commercial, R&D and corporate operations through the first quarter of 2024.

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 at the Pentax Learning Center

Retrieved on: 
Wednesday, June 14, 2023
Suction, Atmosphere, Gastrointestinal disease, EMR, Motus, Endoscopic mucosal resection, Carbon, Pentax, MD, Patient, Physician, Blood, Ecuadorian Institute of Social Security, Mortality, Research, GI, Pharmaceutical industry

The Pure-Vu Gen 4 system will have a new mode called “fluid only” that the user can select when needed to support this new use case of UEMR.

Key Points: 
  • The Pure-Vu Gen 4 system will have a new mode called “fluid only” that the user can select when needed to support this new use case of UEMR.
  • “We are pleased by the positive feedback our Pure-Vu Gen 4 system received from physicians participating in the IECED course 2023,” commented Mark Pomeranz, Chief Executive Officer.
  • “We believe the advanced capabilities of this important next generation of our technology is continuing to generate broad interest in the Pure-Vu system.
  • The Company is also leveraging this Gen 4 technology to enhance the Pure-Vu device in the colon.

Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA Submission

Retrieved on: 
Wednesday, May 17, 2023
Hematochezia, Suction, EURO, Gastrointestinal disease, WEO, ISO, Anatomy, Endoscopic mucosal resection, Endoscopy, Colon, Certification, Pentax, MD, Patient, Physician, EUS, Blood, Ecuadorian Institute of Social Security, Diagnosis, Mortality, Research, GI, Medical device, Medical imaging

FORT LAUDERDALE, Fla., May 17, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced in collaboration with the Ecuadorian Institute of Digestive Diseases (IECED) initiation of a clinical evaluation of the Pure-Vu Gen 4 Gastro, which is designed for upper gastrointestinal (GI) bleeding procedures - an area of high unmet patient need.

Key Points: 
  • “We are excited to initiate this important clinical evaluation of the Pure-Vu Gen 4 Gastro with Dr. Carlos Robles-Medranda and the team at IECED.
  • The focus of these procedures was aimed at evaluating the device’s ability to improve a physician’s visualization while identifying and treating upper GI bleeds.
  • Dr. Robles-Medranda has already successfully conducted his first series of procedures utilizing the Pure-Vu Gen 4 Gastro and provided positive initial feedback on the device’s performance.
  • The procedures in the upper GI tract were efficient for these first time users with the upper procedures averaging only 11 minutes.